Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPACT-MI: Empagliflozin for prevention of heart failure hospitalization and death after acute myocardial infarction
jRCT2071210095Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in myocardial infarction (MI) and heart failure (HF) comparing Empagliflozin arm with Placebo arm (2 arms). Primary endpoint: Composite of time to first hospitalization for heart failure or all-cause mortality. Started Sep 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)heart failure (HF)
Beyond the preview
Go deeper on jRCT2071210095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210095.